Lv2
175 积分 2021-07-14 加入
Carfilzomib induction, consolidation, and maintenance with or without autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma: pre-planned cytogenetic subgroup analysis of the randomised, phase 2 FORTE trial
7天前
已完结
Measurable residual disease monitoring in AML: Prospects for therapeutic decision‐making and new drug development
14天前
已完结
Asciminib plus dasatinib and prednisone for Philadelphia chromosome-positive acute leukemia
17天前
已完结
Asciminib plus dasatinib and prednisone for Philadelphia chromosome-positive acute leukemia
17天前
已关闭
Hematopoietic stem cell transplantation activity in China 2022–2023. The proportions of peripheral blood for stem cell source continue to grow: a report from the Chinese Blood and Marrow Transplantation Registry Group
1个月前
已完结
Attainment of at least a very good partial response after induction treatment is an important surrogate of longer survival for multiple myeloma
1个月前
已关闭
How I treat post-immunotherapy relapsed B-ALL
2个月前
已完结
Lymphoma Classifications, How to Develop a Future Unified Taxonomy
3个月前
已关闭
Bortezomib, thalidomide, and dexamethasone with or without daratumumab and followed by daratumumab maintenance or observation in transplant-eligible newly diagnosed multiple myeloma: long-term follow-up of the CASSIOPEIA randomised controlled phase 3 trial
3个月前
已完结
Minimal Residual Disease Status in Multiple Myeloma 1 Year After Autologous Hematopoietic Cell Transplantation and Lenalidomide Maintenance Are Associated With Long-Term Overall Survival
5个月前
已完结
皖公网安备34019202002308
